Insider Buying: Ocugen (NASDAQ:OCGN) Director Purchases $99,900.00 in Stock

Ocugen (NASDAQ:OCGN) Director Junge Zhang bought 270,000 shares of Ocugen stock in a transaction that occurred on Wednesday, November 27th. The shares were acquired at an average cost of $0.37 per share, for a total transaction of $99,900.00. Following the completion of the transaction, the director now directly owns 600,078 shares in the company, valued at $222,028.86. The transaction was disclosed in a filing with the SEC, which is available at this link.

Junge Zhang also recently made the following trade(s):

  • On Monday, November 25th, Junge Zhang bought 115,000 shares of Ocugen stock. The shares were acquired at an average cost of $0.27 per share, for a total transaction of $31,050.00.
  • On Friday, November 22nd, Junge Zhang bought 80,000 shares of Ocugen stock. The shares were acquired at an average cost of $0.28 per share, for a total transaction of $22,400.00.
  • On Monday, November 18th, Junge Zhang bought 100,000 shares of Ocugen stock. The shares were acquired at an average cost of $0.41 per share, for a total transaction of $41,000.00.
  • On Friday, October 11th, Junge Zhang bought 4,000 shares of Ocugen stock. The shares were acquired at an average cost of $1.82 per share, for a total transaction of $7,280.00.
  • On Monday, September 30th, Junge Zhang bought 31,078 shares of Ocugen stock. The shares were acquired at an average cost of $3.09 per share, for a total transaction of $96,031.02.

Shares of NASDAQ:OCGN opened at $0.43 on Thursday. The company’s 50-day simple moving average is $1.08. Ocugen has a 1 year low of $0.23 and a 1 year high of $34.80.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Several brokerages recently issued reports on OCGN. ValuEngine raised Ocugen from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Chardan Capital began coverage on Ocugen in a research report on Wednesday, November 27th. They set a “buy” rating and a $2.00 target price on the stock.

About Ocugen

Ocugen, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases.

Featured Story: How do analysts define an oversold condition?

Insider Buying and Selling by Quarter for Ocugen (NASDAQ:OCGN)

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.